We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Randomized Study of New Formulation Ophthalmic Cysteamine Hydrochloride for Corneal Cystine Accumulation in Patients With Cystinosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00010426
Recruitment Status : Completed
First Posted : February 2, 2001
Last Update Posted : March 25, 2015
Information provided by:

Study Description
Brief Summary:

OBJECTIVES: I. Determine the proportion of patients with cystinosis who experience a serious adverse effect when treated with a new formulation of cysteamine hydrochloride for corneal cystine accumulation.

II. Determine the proportion of patients with a reduction in corneal crystal density of 1.00 unit when treated with this regimen.

Condition or disease Intervention/treatment
Cystinosis Drug: cysteamine hydrochloride

Detailed Description:

PROTOCOL OUTLINE: This is a randomized, multicenter study Patients are randomized to receive the current formulation of cysteamine hydrochloride as drops in one eye and the new formulation of cysteamine hydrochloride as drops in the other eye.

Patients receive the two formulations of cysteamine hydrochloride in their assigned eyes every hour during waking hours daily for 6 months (safety study) or for 1 year (efficacy study).

Study Design

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Primary Purpose: Treatment
Study Start Date : December 1999
Estimated Study Completion Date : February 2001

Arms and Interventions

Outcome Measures

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   1 Year to 50 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


--Disease Characteristics--

  • Diagnosis of cystinosis with more than 2 nmole half-cystine/mg protein in leukocytes OR presence of corneal crystals consistent with cystinosis and distributed in corneal stroma observed by slit lamp biomicroscopy
  • Clinical history consistent with cystinosis
  • Safety study: History of adherence with current eye drop and follow-up schedule on protocol #86-El-0062 Any crystal density score, including zero, on photographs, that has been stable or improved over the past year
  • Efficacy study: Crystal density score at least 1.00 on photographs Concurrently on cysteamine for at least the past 6 months

--Prior/Concurrent Therapy--

  • No prior cysteamine drops (efficacy study)

--Patient Characteristics--

  • Age: 1 to 50 (safety study) 2 to 12 (efficacy study)
  • Other: Willingness and ability to tolerate corneal photographs
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00010426

Sponsors and Collaborators
FDA Office of Orphan Products Development
Leadiant Biosciences, Inc.
Study Chair: Edward F. Lemanowicz Leadiant Biosciences, Inc.
More Information

ClinicalTrials.gov Identifier: NCT00010426     History of Changes
Other Study ID Numbers: 199/15704
First Posted: February 2, 2001    Key Record Dates
Last Update Posted: March 25, 2015
Last Verified: April 2001

Keywords provided by FDA Office of Orphan Products Development:
rare disease
renal and genitourinary disorders

Additional relevant MeSH terms:
Lysosomal Storage Diseases
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Metabolic Diseases
Cystine Depleting Agents
Molecular Mechanisms of Pharmacological Action